<DOC>
	<DOCNO>NCT01109069</DOCNO>
	<brief_summary>The purpose study determine long-term safety fixed-dose , daily regimen PCI-32765 PO subject B cell lymphoma chronic lymphocytic leukemia/small lymphocytic leukemia ( CLL/SLL ) .</brief_summary>
	<brief_title>Safety Tolerability Study PCI-32765 B Cell Lymphoma Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<criteria>Men woman recurrent surface immunoglobulin positive B cell nonHodgkin 's lymphoma ( NHL ) accord WHO classification ( include , limited , CLL/SLL , Waldenstr√∂m 's macroglobulinemia [ WM ] , mantle cell lymphoma [ MCL ] , diffuse large B cell lymphoma [ DLBCL ) meet requirement roll parent protocol want continue study drug . Female subject childbearing potential must negative serum urine pregnancy test within 3 day first dose study drug agree use dual method contraception study 1 month follow last dose study drug . Post menopausal female ( &gt; 45 year old without menses &gt; 1 year ) surgically sterilize female exempt criterion . Male subject must use effective barrier method contraception study 3 month follow last dose sexually active female childbearing potential . Willing able participate require evaluation procedure study protocol include swallow capsule without difficulty Ability understand purpose risk study provide sign date informed consent authorization use protect health information ( accordance national local patient privacy regulation ) . A lifethreatening illness , medical condition organ system dysfunction , investigator 's opinion , could compromise subject 's safety , interfere absorption metabolism PCI32765 PO , put study outcome undue risk Known history Human Immunodeficiency Virus ( HIV ) active infection Hepatitis C Virus ( HCV ) Hepatitis B Virus ( HBV ) uncontrolled active systemic infection . Lactating pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>PCI-32765</keyword>
	<keyword>Lymphoma , B-Cell</keyword>
	<keyword>Leukemia , Lymphoid</keyword>
	<keyword>Leukemia , B-Cell</keyword>
	<keyword>Bruton 's Tyrosine Kinase</keyword>
</DOC>